Paul McKenzie, CSL Behring CEO
August 13, 2024 09:34 AM EDT
Pharma
Cell/Gene Tx

CSL Behring says up­take of he­mo­phil­ia B gene ther­a­py slow­er than ex­pect­ed

Amber Tong

More than a year af­ter launch­ing the first-ever gene ther­a­py for he­mo­phil­ia B, CSL Behring re­vealed that it’s treat­ed more than 12 pa­tients so far …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

In sur­prise, study sug­gests Covid mR­NA vac­cines may boost can­cer im­munother­a­py ef­fi­ca­cy

Pfiz­er tees up Phase 3 test in weight man­age­ment — but in an un­ex­pect­ed area

Ex-Kite lead­ers step in at Kyver­na as CEO ex­its af­ter land­ing year's sec­ond-biggest IPO

BioN­Tech rolls out Phase 2 lung can­cer da­ta as VEGF bis­pecifics take cen­ter stage

Im­mat­ics los­es Bris­tol My­er­s' sup­port on Phase 1 bis­pe­cif­ic T cell en­gager

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times